Quick Answer
Lyra Therapeutics, Inc. reported Cash and Equivalents of $15.89 million for fiscal year 2025.
Lyra Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.89M | -60.8% |
| 2024 | $40.58M | +81.5% |
| 2023 | $22.35M | -31.3% |
| 2022 | $32.55M | -28.8% |
| 2021 | $45.75M | -38.7% |
| 2020 | $74.59M | +660.5% |
| 2019 | $9.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.05M | -7.3% | -26.0% |
| June 30, 2025 | $29.78M | -6.6% | -6.1% |
| March 31, 2025 | $31.73M | +100.9% | -21.8% |
| December 31, 2024 | $40.58M | +81.5% | +70.5% |
| September 30, 2024 | $23.80M | -4.2% | -25.4% |
| June 30, 2024 | $31.91M | -41.3% | +101.9% |
| March 31, 2024 | $15.80M | -28.2% | -29.3% |
| December 31, 2023 | $22.35M | -31.3% | -10.0% |
- Lyra Therapeutics, Inc. showed a decrease of -60.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Lyra Therapeutics, Inc.’s cash and equivalents has grown by 62.0% (from $9.81 million to $15.89 million).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: